Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Generic Panel to Issue Report in Spring-Summer to Drive Manufacturing Efficiency towards Stable Supplies: Official
February 8, 2024
- Japan to Revamp Scheme for Drug Maker’s Reporting of Supply Concerns in April
February 7, 2024
- Legal Changes on Horizon for GMP Inspection Authorities, Other Regulation Panel Topics?
February 7, 2024
- Govt Eyes Boosted Manpower at AMED towards Next 5-Year Plan from FY2025
February 7, 2024
- AMED Needs More Manpower to Fulfill Its Role as Funding Agency: President
February 6, 2024
- Opdivo, Olumiant, Dupixent Now in Line for Label Expansions
February 6, 2024
- CSL’s Hemophilia Gene Therapy to Get Orphan Tag in Japan
February 6, 2024
- Truvada Clears Preliminary Review for PrEP Use, but Coverage Not Granted
February 6, 2024
- Generic Firms Required to Disclose Supply Info from June after Pilot Rollout of Company Indicators
February 5, 2024
- Will Truvada Win Health Coverage as Japan’s First Drug for HIV Prevention?
February 5, 2024
- MHLW to Kick Off Debates on PMD Act Amendment on Feb. 9
February 5, 2024
- Physician Meals Costs, Seminar Expenses Newly Subject to Disclosure under Clinical Trials Act from April
February 2, 2024
- Annual Drug Price Revisions Based on 4-Minister Agreement: Japan PM
February 2, 2024
- Japan to Introduce Fee Premium for Inpatient Biosimilar Use, Covering 13 APIs
February 1, 2024
- Drug Pricing, LLP Rule in MHLW’s Draft Supplementary Opinions for FY2024 Reform
February 1, 2024
- Japan to Revise Ad Guidelines to Address GLP-1 Use for Cosmetic Weight Loss
January 31, 2024
- MHLW to Require Pharma to Disclose More Categories of Physician Payments under Clinical Trials Act
January 30, 2024
- MEXT’s Draft Reform Guidelines Urge University Hospitals to Reduce Drug Costs
January 29, 2024
- Chuikyo to Discuss Exclusion of Long-Listed Biologics from New Coverage Scheme
January 29, 2024
- Japan’s Diet Kicks Off 150-Day Regular Session, MHLW Plans 4 Bills
January 29, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…